Senseonics announces first patients using integrated twiist AID system, Eversense 365 CGM
By HME News Staff
Updated 9:38 AM CST, Tue January 13, 2026
GERMANTOWN, Md. - Senseonics and Sequel MedTech have launched the integration of their products with the first patients receiving a Sequel twiist automated insulin delivery (AID) system paired with the implantable Eversense 365 continuous glucose monitor (CGM). The companies say pairing twiist with Eversense 365 is the first time the world’s only one year CGM system has been integrated with an AID, representing a major milestone in holistic, long-term diabetes management by reducing the need for regular sensor changes and re-pairing, while maintaining exceptional accuracy. “While our technologies are unique, our goal is the same - to improve lives and reduce complexity for patients living with diabetes,” said Tim Goodnow, president and CEO of Senseonics. “We are proud to partner with Sequel and provide the necessary glucose monitoring data to power the twiist Loop algorithm, which enables real-time insulin delivery decisions through the twiist pump. Patients and providers want reliable, long-term automated glucose readings and we’ve taken a major step forward in simplifying and personalizing diabetes management by integrating Eversense 365’s One Year CGM system with the twiist AID system for patients that require insulin.” Broad availability of twiist with Eversense 365 is expected by March 2026. For more information on availability please visit https://www.eversensecgm.com/partners/ or visit.twiist.com/eversense365.
Comments